Calidi Biotherapeutics Stock Probability of Future Stock Price Finishing Over 0.78
| CLDI Stock | 0.78 0.02 2.63% |
Calidi Biotherapeutics Target Price Odds to finish over 0.78
The tendency of Calidi Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.78 | 90 days | 0.78 | about 97.0 |
Based on a normal probability distribution, the odds of Calidi Biotherapeutics to move above the current price in 90 days from now is about 97.0 (This Calidi Biotherapeutics probability density function shows the probability of Calidi Stock to fall within a particular range of prices over 90 days) .
Calidi Biotherapeutics Price Density |
| Price |
Predictive Modules for Calidi Biotherapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Calidi Biotherapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Calidi Biotherapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Calidi Biotherapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Calidi Biotherapeutics is not an exception. The market had few large corrections towards the Calidi Biotherapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Calidi Biotherapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Calidi Biotherapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.91 | |
β | Beta against Dow Jones | 1.42 | |
σ | Overall volatility | 0.23 | |
Ir | Information ratio | -0.25 |
Calidi Biotherapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Calidi Biotherapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Calidi Biotherapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Calidi Biotherapeutics generated a negative expected return over the last 90 days | |
| Calidi Biotherapeutics has some characteristics of a very speculative penny stock | |
| Calidi Biotherapeutics has high historical volatility and very poor performance | |
| Calidi Biotherapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (22.21 M) with profit before overhead, payroll, taxes, and interest of 31 K. | |
| Calidi Biotherapeutics generates negative cash flow from operations | |
| About 23.0% of the company shares are held by company insiders | |
| Latest headline from fnarena.com: Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader |
Calidi Biotherapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Calidi Stock often depends not only on the future outlook of the current and potential Calidi Biotherapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Calidi Biotherapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 664.4 K | |
| Cash And Short Term Investments | 9.6 M |
Calidi Biotherapeutics Technical Analysis
Calidi Biotherapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Calidi Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Calidi Biotherapeutics. In general, you should focus on analyzing Calidi Stock price patterns and their correlations with different microeconomic environments and drivers.
Calidi Biotherapeutics Predictive Forecast Models
Calidi Biotherapeutics' time-series forecasting models is one of many Calidi Biotherapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Calidi Biotherapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Calidi Biotherapeutics
Checking the ongoing alerts about Calidi Biotherapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Calidi Biotherapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Calidi Biotherapeutics generated a negative expected return over the last 90 days | |
| Calidi Biotherapeutics has some characteristics of a very speculative penny stock | |
| Calidi Biotherapeutics has high historical volatility and very poor performance | |
| Calidi Biotherapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (22.21 M) with profit before overhead, payroll, taxes, and interest of 31 K. | |
| Calidi Biotherapeutics generates negative cash flow from operations | |
| About 23.0% of the company shares are held by company insiders | |
| Latest headline from fnarena.com: Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader |
Check out Calidi Biotherapeutics Analysis, Calidi Biotherapeutics Valuation, Calidi Biotherapeutics Correlation, Calidi Biotherapeutics Hype Analysis, Calidi Biotherapeutics Volatility, Calidi Biotherapeutics Price History as well as Calidi Biotherapeutics Performance. For more detail on how to invest in Calidi Stock please use our How to Invest in Calidi Biotherapeutics guide.You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is there potential for Biotechnology market expansion? Will Calidi introduce new products? Factors like these will boost the valuation of Calidi Biotherapeutics. Projected growth potential of Calidi fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about Calidi Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Understanding Calidi Biotherapeutics requires distinguishing between market price and book value, where the latter reflects Calidi's accounting equity. The concept of intrinsic value - what Calidi Biotherapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push Calidi Biotherapeutics' price substantially above or below its fundamental value.
It's important to distinguish between Calidi Biotherapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Calidi Biotherapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Calidi Biotherapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.